Last reviewed · How we verify
Xtampza ER
Xtampza ER is an extended-release formulation of oxycodone that provides prolonged opioid analgesia through mu-opioid receptor agonism.
Xtampza ER is an extended-release formulation of oxycodone that provides prolonged opioid analgesia through mu-opioid receptor agonism. Used for Moderate to severe chronic pain requiring long-term opioid therapy.
At a glance
| Generic name | Xtampza ER |
|---|---|
| Sponsor | University of Alabama at Birmingham |
| Drug class | Opioid analgesic, abuse-deterrent formulation |
| Target | Mu-opioid receptor (μ-OR) |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | FDA-approved |
Mechanism of action
Xtampza ER uses proprietary abuse-deterrent technology (Xtreme Abuse Resistant formulation) to deliver oxycodone over an extended period, reducing the frequency of dosing while maintaining pain relief. The formulation is designed to resist common methods of abuse such as crushing, dissolving, or extracting the drug, making it more difficult to misuse compared to conventional extended-release opioids.
Approved indications
- Moderate to severe chronic pain requiring long-term opioid therapy
Common side effects
- Constipation
- Nausea
- Dizziness
- Drowsiness
- Vomiting
Key clinical trials
- Examining Analgesic Synergy and Efficacy in Trauma Care (PHASE4)
- Serratus Plane Block (SPB) Versus Capsaïcine Versus Botox-A for Chronic Neuropathic Pain in Post-mastectomy Syndrome (PHASE2)
- Intercostal Nerve Cryoablation Versus Epidural Analgesia for Nuss Repair of Pectus Excavatum (NA)
- Effect of CYP2D6 on Perioperative Analgesia of Oxycodone in Elderly Patients
- Nonopioid Analgesia After Anterior Cruciate Ligament Reconstruction (PHASE2, PHASE3)
- Efficacy And Safety Of Tramadol And Oxycodone Versus Oxycodone Monotherapy For Pain Control After Primary Total Knee And Total Hip Arthroplasty (PHASE4)
- The Efficacy and Safety of Liposomal Bupivacaine for Transversus Abdominis Plane Block in Relieving Postoperative Pain After Laparoscopic Surgery (NA)
- The Efficacy and Safety of Liposomal Bupivacaine for Transversus Abdominis Plane Block in Relieving Postoperative Pain After Laparoscopic Surgery in Gynecologic Oncology (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Xtampza ER CI brief — competitive landscape report
- Xtampza ER updates RSS · CI watch RSS
- University of Alabama at Birmingham portfolio CI